Guizhou Yibai Pharmaceutical Co Ltd (600594) - Net Assets

Latest as of March 2026: CN¥2.24 Billion CNY ≈ $328.02 Million USD

Based on the latest financial reports, Guizhou Yibai Pharmaceutical Co Ltd (600594) has net assets worth CN¥2.24 Billion CNY (≈ $328.02 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.40 Billion ≈ $497.27 Million USD) and total liabilities (CN¥1.16 Billion ≈ $169.24 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore 600594 cash flow conversion to assess how effectively this company generates cash.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥2.24 Billion
% of Total Assets	65.97%
Annual Growth Rate	14.8%
5-Year Change	-36.26%
10-Year Change	-45.84%
Growth Volatility	41.0

Guizhou Yibai Pharmaceutical Co Ltd - Net Assets Trend (2001–2025)

This chart illustrates how Guizhou Yibai Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Guizhou Yibai Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Guizhou Yibai Pharmaceutical Co Ltd (2001–2025)

The table below shows the annual net assets of Guizhou Yibai Pharmaceutical Co Ltd from 2001 to 2025. For live valuation and market cap data, see 600594 company net worth.

Year	Net Assets	Change
2025-12-31	CN¥2.27 Billion ≈ $332.26 Million	-12.87%
2024-12-31	CN¥2.61 Billion ≈ $381.36 Million	-13.66%
2023-12-31	CN¥3.02 Billion ≈ $441.67 Million	-5.38%
2022-12-31	CN¥3.19 Billion ≈ $466.79 Million	-10.46%
2021-12-31	CN¥3.56 Billion ≈ $521.30 Million	+2.87%
2020-12-31	CN¥3.46 Billion ≈ $506.76 Million	-6.98%
2019-12-31	CN¥3.72 Billion ≈ $544.80 Million	-4.80%
2018-12-31	CN¥3.91 Billion ≈ $572.24 Million	-15.75%
2017-12-31	CN¥4.64 Billion ≈ $679.20 Million	+10.70%
2016-12-31	CN¥4.19 Billion ≈ $613.53 Million	+18.10%
2015-12-31	CN¥3.55 Billion ≈ $519.48 Million	+3.67%
2014-12-31	CN¥3.42 Billion ≈ $501.09 Million	+77.20%
2013-12-31	CN¥1.93 Billion ≈ $282.78 Million	+25.03%
2012-12-31	CN¥1.55 Billion ≈ $226.16 Million	+35.79%
2011-12-31	CN¥1.14 Billion ≈ $166.55 Million	+29.92%
2010-12-31	CN¥876.05 Million ≈ $128.19 Million	+23.22%
2009-12-31	CN¥710.95 Million ≈ $104.03 Million	+18.86%
2008-12-31	CN¥598.16 Million ≈ $87.53 Million	+12.85%
2007-12-31	CN¥530.04 Million ≈ $77.56 Million	+24.51%
2006-12-31	CN¥425.69 Million ≈ $62.29 Million	-22.23%
2005-12-31	CN¥547.39 Million ≈ $80.10 Million	+8.03%
2004-12-31	CN¥506.70 Million ≈ $74.15 Million	+181.16%
2003-12-31	CN¥180.22 Million ≈ $26.37 Million	+40.57%
2002-12-31	CN¥128.20 Million ≈ $18.76 Million	+55.15%
2001-12-31	CN¥82.63 Million ≈ $12.09 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Guizhou Yibai Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1301.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥424.42 Million	19.40%
Other Components	CN¥1.76 Billion	80.60%
Total Equity	CN¥2.19 Billion	100.00%

Guizhou Yibai Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Guizhou Yibai Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Sappi Ltd JSE:SAP	$409.10 Million
Costamare Bulkers Holdings Limited NYSE:CMDB	$409.38 Million
Shanghai Kehua Bio-Engineering Co Ltd SHE:002022	$409.45 Million
Atrium Mortgage Investment Corp TO:AI	$409.50 Million
Burstone Group Limited JSE:BTN	$409.01 Million
Guangdong Failong Crystal Technology Co Ltd SHE:300460	$408.85 Million
NACL Industries Limited NSE:NACLIND	$408.83 Million
Beijing Succeeder Technology Inc SHG:688338	$408.80 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Guizhou Yibai Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 2,489,758,456 to 2,187,786,874, a change of -301,971,582 (-12.1%).
Net loss of 329,562,326 reduced equity.
Dividend payments of 28,686,363 reduced retained earnings.
Other comprehensive income decreased equity by 315,015,845.
Other factors increased equity by 371,292,953.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥-329.56 Million	-15.06%
Dividends Paid	CN¥28.69 Million	-1.31%
Other Comprehensive Income	CN¥-315.02 Million	-14.4%
Other Changes	CN¥371.29 Million	+16.97%
Total Change	CN¥-	-12.13%

Book Value vs Market Value Analysis

This analysis compares Guizhou Yibai Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.28x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 20.10x to 1.28x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-12-31	CN¥0.18	CN¥3.53	x
2002-12-31	CN¥0.27	CN¥3.53	x
2003-12-31	CN¥0.38	CN¥3.53	x
2004-12-31	CN¥1.08	CN¥3.53	x
2005-12-31	CN¥1.18	CN¥3.53	x
2006-12-31	CN¥0.90	CN¥3.53	x
2007-12-31	CN¥0.94	CN¥3.53	x
2008-12-31	CN¥0.82	CN¥3.53	x
2009-12-31	CN¥0.99	CN¥3.53	x
2010-12-31	CN¥1.23	CN¥3.53	x
2011-12-31	CN¥1.60	CN¥3.53	x
2012-12-31	CN¥2.14	CN¥3.53	x
2013-12-31	CN¥2.67	CN¥3.53	x
2014-12-31	CN¥4.31	CN¥3.53	x
2015-12-31	CN¥4.47	CN¥3.53	x
2016-12-31	CN¥4.92	CN¥3.53	x
2017-12-31	CN¥5.34	CN¥3.53	x
2018-12-31	CN¥4.36	CN¥3.53	x
2019-12-31	CN¥4.54	CN¥3.53	x
2020-12-31	CN¥4.25	CN¥3.53	x
2021-12-31	CN¥4.43	CN¥3.53	x
2022-12-31	CN¥3.84	CN¥3.53	x
2023-12-31	CN¥3.65	CN¥3.53	x
2024-12-31	CN¥3.16	CN¥3.53	x
2025-12-31	CN¥2.76	CN¥3.53	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Guizhou Yibai Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -15.06%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -17.69%
• Asset Turnover: 0.54x
• Equity Multiplier: 1.57x
Recent ROE (-15.06%) is below the historical average (9.47%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	41.21%	12.31%	1.27x	2.64x	CN¥25.79 Million
2002	35.55%	10.27%	1.46x	2.36x	CN¥32.75 Million
2003	28.68%	10.26%	1.10x	2.53x	CN¥33.58 Million
2004	11.10%	8.92%	0.73x	1.71x	CN¥5.58 Million
2005	12.48%	9.39%	0.62x	2.16x	CN¥13.79 Million
2006	-31.77%	-18.76%	0.73x	2.33x	CN¥-176.87 Million
2007	18.12%	9.22%	0.88x	2.23x	CN¥41.57 Million
2008	16.94%	8.50%	0.95x	2.10x	CN¥40.19 Million
2009	17.37%	9.32%	1.02x	1.83x	CN¥51.69 Million
2010	22.58%	13.33%	0.94x	1.81x	CN¥108.94 Million
2011	23.58%	13.95%	1.06x	1.60x	CN¥152.89 Million
2012	21.66%	14.79%	0.99x	1.48x	CN¥179.39 Million
2013	22.31%	15.41%	0.87x	1.66x	CN¥236.77 Million
2014	14.02%	15.15%	0.57x	1.61x	CN¥137.14 Million
2015	5.35%	5.73%	0.59x	1.58x	CN¥-164.28 Million
2016	9.89%	10.44%	0.56x	1.69x	CN¥-4.44 Million
2017	9.16%	10.18%	0.53x	1.70x	CN¥-35.74 Million
2018	-20.99%	-18.68%	0.60x	1.87x	CN¥-1.07 Billion
2019	3.94%	4.22%	0.60x	1.56x	CN¥-218.18 Million
2020	6.80%	6.70%	0.65x	1.55x	CN¥-107.76 Million
2021	6.96%	7.28%	0.66x	1.45x	CN¥-106.55 Million
2022	-14.01%	-15.59%	0.56x	1.60x	CN¥-730.81 Million
2023	3.58%	3.67%	0.61x	1.59x	CN¥-185.05 Million
2024	-12.74%	-14.59%	0.53x	1.65x	CN¥-566.19 Million
2025	-15.06%	-17.69%	0.54x	1.57x	CN¥-548.34 Million

Industry Comparison

This section compares Guizhou Yibai Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $2,064,064,076
Average return on equity (ROE) among peers: 1.80%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Guizhou Yibai Pharmaceutical Co Ltd (600594)	CN¥2.24 Billion	41.21%	0.52x	$409.07 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$6.47 Billion	9.84%	3.77x	$585.22 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$654.09 Million	2.17%	0.78x	$387.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$108.44 Million	15.88%	0.98x	$4.64 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.07 Billion	3.83%	0.46x	$2.63 Billion
Wedge Industrial Co Ltd (000534)	$1.55 Billion	12.44%	1.56x	$2.48 Billion
Yunnan Baiyao Group Co Ltd (000538)	$9.03 Billion	25.71%	0.43x	$12.98 Billion
Hainan Haiyao Co Ltd (000566)	$294.63 Million	-32.00%	2.31x	$772.67 Million
Tus Pharmaceutical Group Co Ltd (000590)	$231.22 Million	-38.13%	1.23x	$352.87 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$994.58 Million	2.01%	2.11x	$960.61 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$243.07 Million	16.30%	0.73x	$3.03 Billion

About Guizhou Yibai Pharmaceutical Co Ltd

SHG:600594 China Drug Manufacturers - Specialty & Generic

Market Cap

$409.07 Million

CN¥2.80 Billion CNY

Market Cap Rank

#13553 Global

#4147 in China

Share Price

CN¥3.53

Change (1 day)

-1.40%

52-Week Range

CN¥3.45 - CN¥5.06

All Time High

CN¥19.64